Back to School: How biopharma can reboot drug development. Access exclusive analysis here
NitroMed (NTMD) proposed to raise $65.2 million in a follow-on underwritten by JP Morgan; Pacific Growth; Deutsche Bank; and
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury